Two-year stability of free and total PSA in frozen serum samples

Urology

Volumn 52, Issue 2, 1998, Pages 247-251

  Woodrum, David ^a   York, Lisa ^a  

^a Hybritech Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATITIS; SERUM;

AGED; AGED, 80 AND OVER; BLOOD PRESERVATION; CRYOPRESERVATION; HUMANS; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; REGRESSION ANALYSIS; TIME FACTORS;

EID: 0032145290     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00156-3     Document Type: Article

References (24)

1. Catalona W.J., Ritchie J., Ahmann F.K., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
2. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 270:1993;948-954.
3. Woodrum D.L., Brawer M.K., Partin A.W., et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 159:1998;5-12.
4. Stenman U.H., Leinonen J., Alfthan H., et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer assay of the complex improves clinical sensitivity for cancer . Cancer Res. 51:1991;222-226.
5. Christensson A., Bjork T., Nilsson O., et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 150:1993;100-105.
6. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
7. Luderer A.A., Chen Y.T., Soriano T.F., et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology. 46:1995;187-194.
8. Prestiagiacomo A.F., Lilja H., Pettersson K., et al. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates the best case scenario . J Urol. 156:1996;350-354.
9. Elgamal A.A., Cornillie F.J., Van Poppel H.P., et al. Free-to-total prostate specific antigen ratio as a single test for detection of significant T1c prostate cancer. J Urol. 156:1996;1042-1049.
10. Van Cangh P.J., De Nayer P., Sauvage P., et al. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate Suppl. 7:1996;30-34.
11. Partin A.W., Catalona W.J., Southwick P.C., et al. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection influence of total PSA, prostate volume, and age . Urology. 48:(suppl 6A):1996;55-61.
12. Chen Y.T., Luderer A.A., Theil R.P., et al. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology. 47:1996;518-524.
13. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostatic examination. Enhancement of specificity with free PSA measurements. JAMA. 277:1997;1452-1455.
14. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of percent free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease a prospective multicenter clinical trial . JAMA. 279:1998;1542-1547.
15. Woodrum D.L., French C.F., Hill T.M., et al. Analytical performance of the Tandem®-R free PSA immunoassay measuring free prostate specific antigen. Clin Chem. 43:1997;1203-1208.
16. Woodrum D., French C., Shamel L.B. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology. 48:(suppl 6A):1996;33-39.
17. 1-antichymotrypsin in blood samples. Urology. 48:(suppl 6A):1996;81-87.
18. Arcangeli C.G., Smith D.S., Ratliff T.L., et al. Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol. 158:1997;2182-2187.
19. Van der Horst F.A.L., van Adrichem N.P.H., Butenhuis A., et al. Study on the stability of free PSA in sera. Clin Chem. 42:(suppl 6):1996;S267.
20. Borchers H., Brehmer B., Jaske G., et al. Stability of free and total PSA in serum. J Urol. 157:(suppl 4):1997;62A.
21. Witherspoon L.R., Lohmann T.P., Lapeyrolerie T. Stability of free prostate specific antigen (FPSA) as estimated by IMMULITE (IMM) (Diagnostic Products Corporation). Clin Chem. 43:(suppl 6):1997;S236.
22. McCormack R.T., Rittenhouse H.G., Finlay J.A., et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family a new era . Urology. 45:1995;729-744.
23. Pettersson K., Piironen T., Seppala M., et al. Free and complexed prostate-specific antigen (PSA) in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex . Clin Chem. 41:1995;1480-1488.
24. Pearson J.D., Luderer A.A., Metter J.E., et al. Longitudinal measurements of free and total PSA among men with and without prostatic cancer. Urology. 48:(suppl 6A):1996;4-9.